Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Oklahoma: - University of Oklahoma Health Sciences, Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05379595
Sites in Oklahoma: - Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Oklahoma: - Sarah Cannon Research Institute - Oklahoma University — Oklahoma City, Oklahoma
Phase 1 Recruiting NIH
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04704661
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other pl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05803382
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Oklahoma: - Xencor Investigative Site — Oklahoma City, Oklahoma
Phase 1 Recruiting NIH
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has co…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06102902
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting NIH
This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first s…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06696768
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…
Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in Oklahoma: - Oklahoma University Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oklahoma: - Massive Bio SYNERGY-AI site — Tulsa, Oklahoma
NA Recruiting Academic/Other
The Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS) Program addresses major regional CRC screening disparities among AI in Oklahoma. The investigators are engaged in a participatory and collab…
Sponsor: University of Oklahoma
NCT ID: NCT07254910
Sites in Oklahoma: - TSET Health Promotion Research Center — Oklahoma City, Oklahoma